PGP and neoplasm: In the present study we tested whether the combined treatment with CsA and UIC2 mAb can potentiate the anti-tumor effect of doxorubicin (DOX) in Pgp+ tumors to achieve clinically relevant reduction in tumor size, applying the above experimental model [22].